CTIS2024-515456-20-00进行中（未招募）1 期
Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion : Phase II, single arm, Multicentric - LIDA-BII
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically-proven HCC or according to EASL criteria, Absence of heart failure (Ultrasound LVEF > 50%), Women of child-bearing age using an adequate method of contraception throughout treatment and 6.5 months after treatment, Men using an adequate method of contraception throughout the treatment and at least 3,5 months after the end of treatment, Written informed consent, National health insurance cover (France), Child-Pugh A or B7, Disease that is not suitable for resection, ablation or radiofrequency, Performance Status ECOG 0 or 1, BCLC A/B or C if Performance Status ECOG = 1, Measurable lesions according to mRECIST criteria, No previous treatment with chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy) or radioembolisation, Age superior or equal to 18 years, Platelets > 50,000/mm3, Polynuclear neutrophils > 1000/mm3, Creatininemia < 150umol/L, Bilirubinemia < 5 mg/d
排除标准
- •Advanced tumor disease (extrahepatic except pulmonary micronodules <7mm of tumoral portal vein thrombosis on positron emission tomography are not a contra-indication.), Uncontrolled severe infection, Vascular anatomy makes it impossible to perform hepatic intra-arterial treatments, Grade 2 or 3 oesograstric varices on the last endoscopy less than 3 months old., Pregnancy (Beta HCG positive) or breastfeeding, Patient who for psychological, social, family or geographical reasons cannot be followed regularly, Vulnerable person, Concomitant participation of the patient in another research involving the human person, Large HCC with liver invasion >50%, History of other cancer than HCC and excluding cancers known to have been cured for more than 5 years, or basocellular skin tumors or cervical cancer in situ treated with adequate and curative purpose, Advanced liver disease (Child B8, B9 or C), Contra-indication for the MRI (Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreing body similar to the nervous structure), Contra-indication to the injection of the gadolinium-based contrast agents (history of hypersensibility to the gadolinium chelates, meglumine)., Contra-indication to idarubicin (Hypersensibility to active substance or excipients, cardiopathy with myocardial insufficiency of less than 6 months, serious arrhythmias, serious renal or liver failure, yellow fever vaccine or any other live attenuated vaccine, persistente myelosuppression, previous treatments with idarubicin and/or other anthracyclines or anthracenediones at maximum cumulative doses, stomatitis), Contra-indication to Lipiodol (Hypersensibility, proven hyperthyroidism, tromatic injuries, bleeding or recent bleeding), Concomitant disease or uncontrolled severe clinical situation
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the efficacy and tolerance of a chemotherapy by Idarubicin and Lipiodol emulsion administer in the liver, by the hepatic artery, on hepatocellular carcinoma.The research hypothesis is that hepatic locoregional treatment without embolization, using a more cytotoxic anticancer molecule (Idarubicin) than those conventionally used, would be more effective.MedDRA version: 20.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864EUCTR2017-004859-22-FRniversity Hospital of Monptellier53
招募中
不适用
Carcinome hépatocellulaire avancé sur cirrhose Child B : étude de tolérance et d’efficacité du Torisel® (Temsirolimus) - FFCD 0903Carcinome hépatocellulaire avancé sur cirrhose Child B, CHC non accessible à un autre traitement (chirurgie, radiofréquence, chimioembolisation)EUCTR2009-014443-36-FRFrancophone de Cancérologie Digestive (FFCD)
Unknown
3 期
Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin AloneCarcinoma, HepatocellularNCT00121914Medical University of Vienna120
Unknown
不适用
Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.Antiviral Drug Adverse ReactionHepatitis CCirrhosisNCT03775798Austral University, Argentina2,200
招募中
不适用
Risk assessment of hepatocellular carcinoma in chronic liver disease by using liver stiffness measurementChronic liver diseaseJPRN-UMIN000029437Department of Gastroenterology and Hepatology,Hokkaido University Hospital2,000